Masupirdine mesylate is primarily investigated for its potential in treating neurological and psychiatric disorders. It functions as a selective antagonist of the 5-HT2C receptor, which plays a key role in mood regulation, sleep, and appetite. Due to this mechanism, it has been explored in clinical trials for the treatment of major depressive disorder, particularly in patients who have not responded well to standard antidepressants. Its action on serotonin pathways may offer a faster onset of antidepressant effects compared to conventional therapies. Additionally, masupirdine mesylate has shown promise in improving sleep architecture, making it a candidate for depression-associated insomnia. Research is ongoing to determine its full therapeutic potential and safety profile in long-term use.